These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 22969221)

  • 1. Early administration of branched-chain amino acid granules.
    Ishikawa T
    World J Gastroenterol; 2012 Sep; 18(33):4486-90. PubMed ID: 22969221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the branched-chain amino acid to tyrosine ratio and branched-chain amino acid granule therapy in patients with hepatocellular carcinoma: A propensity score analysis.
    Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1412-9. PubMed ID: 25799910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Easy clinical predictor for low BCAA to tyrosine ratio in chronic liver disease patients with hepatocellular carcinoma: Usefulness of ALBI score as nutritional prognostic marker.
    Hiraoka A; Kato M; Marui K; Murakami T; Onishi K; Adachi T; Matsuoka J; Ueki H; Yoshino T; Tsuruta M; Aibiki T; Okudaira T; Kuroda T; Iwasaki R; Suga Y; Miyata H; Ninomiya T; Hirooka M; Abe M; Matsuura B; Michitaka K; Hiasa Y
    Cancer Med; 2021 Jun; 10(11):3584-3592. PubMed ID: 33960691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of oral branched-chain amino acid granules on event-free survival in patients with liver cirrhosis.
    Muto Y; Sato S; Watanabe A; Moriwaki H; Suzuki K; Kato A; Kato M; Nakamura T; Higuchi K; Nishiguchi S; Kumada H;
    Clin Gastroenterol Hepatol; 2005 Jul; 3(7):705-13. PubMed ID: 16206505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effect of BCAA granules on between decompensated and compensated cirrhosis.
    Habu D; Nishiguchi S; Nakatani S; Lee C; Enomoto M; Tamori A; Takeda T; Ohfuji S; Fukushima W; Tanaka T; Kawamura E; Shiomi S
    Hepatogastroenterology; 2009; 56(96):1719-23. PubMed ID: 20214224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating response to nutritional therapy using the branched-chain amino acid/tyrosine ratio in patients with chronic liver disease.
    Kawamura-Yasui N; Kaito M; Nakagawa N; Fujita N; Ikoma J; Gabazza EC; Watanabe S; Adachi Y
    J Clin Lab Anal; 1999; 13(1):31-4. PubMed ID: 10025735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Enzymatic determination of a molar ratio of free branched-chain amino acids to tyrosine (BTR) and its clinical significance in plasma of patients with various liver diseases].
    Nakamura T; Mori M; Yoshida T; Murakami N; Kato T; Sugihara J; Saito K; Moriwaki H; Tomita E; Muto Y
    Rinsho Byori; 1989 Aug; 37(8):911-7. PubMed ID: 2585754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Branched-chain amino acids as a protein- and energy-source in liver cirrhosis.
    Moriwaki H; Miwa Y; Tajika M; Kato M; Fukushima H; Shiraki M
    Biochem Biophys Res Commun; 2004 Jan; 313(2):405-9. PubMed ID: 14684176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral branched-chain amino acid granules reduce the incidence of hepatocellular carcinoma and improve event-free survival in patients with liver cirrhosis.
    Hayaishi S; Chung H; Kudo M; Ishikawa E; Takita M; Ueda T; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Ueshima K
    Dig Dis; 2011; 29(3):326-32. PubMed ID: 21829025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of oral supplementation with branched-chain amino acid granules in the early stage of cirrhosis.
    Nishiguchi S; Habu D
    Hepatol Res; 2004 Dec; 30S():36-41. PubMed ID: 15607137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus.
    Kobayashi M; Ikeda K; Arase Y; Suzuki Y; Suzuki F; Akuta N; Hosaka T; Murashima N; Saitoh S; Someya T; Tsubota A; Kumada H
    J Gastroenterol; 2008; 43(1):63-70. PubMed ID: 18297438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nocturnal branched-chain amino acid administration improves protein metabolism in patients with liver cirrhosis: comparison with daytime administration.
    Fukushima H; Miwa Y; Ida E; Kuriyama S; Toda K; Shimomura Y; Sugiyama A; Sugihara J; Tomita E; Moriwaki H
    JPEN J Parenter Enteral Nutr; 2003; 27(5):315-22. PubMed ID: 12971730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of nocturnal administration of branched-chain amino acid granules to improve quality of life in patients with cirrhosis.
    Hidaka H; Nakazawa T; Kutsukake S; Yamazaki Y; Aoki I; Nakano S; Asaba N; Minamino T; Takada J; Tanaka Y; Okuwaki Y; Watanabe M; Shibuya A; Koizumi W
    J Gastroenterol; 2013 Feb; 48(2):269-76. PubMed ID: 22825550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of long-term oral supplementation with branched-chain amino acid granules on the prognosis of liver cirrhosis.
    Yoshida T; Muto Y; Moriwaki H; Yamato M
    Gastroenterol Jpn; 1989 Dec; 24(6):692-8. PubMed ID: 2606303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of granular BCAA after hepatectomy for liver cancer complicated with liver cirrhosis.
    Togo S; Tanaka K; Morioka D; Sugita M; Ueda M; Miura Y; Kubota T; Nagano Y; Matsuo K; Endo I; Sekido H; Shimada H
    Nutrition; 2005 Apr; 21(4):480-6. PubMed ID: 15811769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Branched-Chain Amino Acid-Enriched Nutrient on liver Cirrhosis with Hepatocellular Carcinoma Undergoing Transcatheter Arterial Chemoembolization in Barcelona Clinic Liver Cancer Stage B: A Prospective Study.
    Shiozawa S; Usui T; Kuhara K; Tsuchiya A; Miyauchi T; Kono T; Asaka S; Yamaguchi K; Yokomizo H; Shimakawa T; Yoshimatsu K; Katsube T; Naritaka Y
    J Nippon Med Sch; 2016; 83(6):248-256. PubMed ID: 28133005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Branched-Chain Amino Acid Granule Therapy in Patients with Hepatocellular Carcinoma Who Have Normal Albumin Levels and Low Branched-Chain Amino Acid to Tyrosine Ratios.
    Tada T; Kumada T; Toyoda H; Yasuda S; Koyabu T; Nakashima M
    Nutr Cancer; 2019; 71(7):1132-1141. PubMed ID: 30955354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Branched-chain amino acids prevent hepatocarcinogenesis and prolong survival of patients with cirrhosis.
    Kawaguchi T; Shiraishi K; Ito T; Suzuki K; Koreeda C; Ohtake T; Iwasa M; Tokumoto Y; Endo R; Kawamura NH; Shiraki M; Habu D; Tsuruta S; Miwa Y; Kawaguchi A; Kakuma T; Sakai H; Kawada N; Hanai T; Takahashi S; Kato A; Onji M; Takei Y; Kohgo Y; Seki T; Tamano M; Katayama K; Mine T; Sata M; Moriwaki H; Suzuki K
    Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1012-8.e1. PubMed ID: 24036055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the branched-chain amino acid-to-tyrosine ratio prior to treatment as a prognostic predictor in patients with liver cirrhosis.
    Ishikawa T; Imai M; Ko M; Sato H; Nozawa Y; Sano T; Iwanaga A; Seki K; Honma T; Yoshida T
    Oncotarget; 2017 Oct; 8(45):79480-79490. PubMed ID: 29108327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy.
    Kanekawa T; Nagai H; Kanayama M; Sumino Y
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):899-909. PubMed ID: 25138286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.